【原著・著書・総説】

1.  Yamanishi Y, Miyaue N, Choudhury ME, Nagai M.
Disease duration-dependent alteration of regulatory natural killer cells in patients with Parkinson’s disease.
Parkinsonism Relat Disord. 2026;147:108322.  doi: 10.1016/j.parkreldis.2026.108322.

2.  Yamanishi Y, Miyaue N, Ochi C, Ito Y, Ando R, Nagai M.
Coexistence of Parkinson’s Disease and Myasthenia Gravis with Symptom Exacerbation Induced by Biperiden: A Case Report.
Intern Med. 2026 May 23.  doi: 10.2169/internalmedicine.7260-26. Online ahead of print.

3.  Yoshida A, Miyaue N, Ito Y, Yabe H.
Association between periventricular white matter hyperintensities around the anterior horn and CSF tap test responsiveness in idiopathic normal pressure hydrocephalus.
J Neurol Sci. 2026;486:125908.  doi: 10.1016/j.jns.2026.125908.

4.  Yoshida A, Miyaue N, Ito Y, Yabe H.
Reply to the comment on “Association between periventricular white matter hyperintensities around the anterior horn and CSF tap test responsiveness in idiopathic normal pressure hydrocephalus”.
J Neurol Sci. 2026;488:126011.  doi: 10.1016/j.jns.2026.126011.

5.  Choudhury ME, Takenaga A, Yamamoto H, Yamauchi H, Koga E, Abe N, Miyaue N, Matsumoto S, Sekiya K, Kusakawa A, Tokunaga N, Tanaka K, Kunieda T, Nagai M, Tanaka J, Nishihara T.
A Dopamine D1-Like Receptor Agonist Ameliorates Traumatic Brain Injury Through its Immunosuppressive Effects.
Cell Mol Neurobiol. 2026;46:60.  doi: 10.1007/s10571-026-01690-1.

6.  Tahara D, Tahara N, Tamai C, Akagi A, Riku Y, Miyahara H, Kobayashi R, Okada H, Kawamoto M, Ishii J, Yamazaki H, Kurashige T, Sugiyama A, Nagaishi A, Nishida K, Sugie K, Fukudome T, Hasegawa K, Ishiura H, Koike H, Kasai T, Mizuno T, Ando M, Higuchi Y, Tanaka F, Izumi Y, Sobue G, Iwasaki Y, Ito S, Sone J; Japanese Consortium for Neuronal Intranuclear Inclusion Disease Study (JaNIIDS) Group (including Miyaue N).
Asthma-like bronchodilator responsiveness in patients with neuronal intranuclear inclusion disease.
Sci Rep. 2026;16:16760.  doi: 10.1038/s41598-026-46319-x.

7.  Miyaue N, Yabe H, Yasugi M, Nagai M.
Serum GDF-15 Levels Correlate With Motor and Nonmotor Symptom Domains and Overall Disease Severity in Patients With Parkinson’s Disease.
Parkinsons Dis. 2026:9949931.  doi: 10.1155/padi/9949931.

8.  Ihara Y, Miyaue N, Ihara M, Kurata T, Nagai M.
Association of probiotic medication use with incident Parkinson disease and alzheimer disease: a nationwide nested case-control study.
J Neurol. 2026;273(6):349.  doi: 10.1007/s00415-026-13899-7.

【学会・研究会】

1.  第15回日本パーキンソン病・運動障害疾患学会教育研修会,米子,4.5,2026.
・永井将弘
パーキンソン病の薬物治療

2.  第67回日本神経学会学術大会,横浜,5.20-5.23,2026.
・永井将弘
シンポジウム「脳神経内科Ｘファーマコゲノミクス（PGx）」
パーキンソン病治療におけるゲノム薬理学（PGx）の臨床応用と課題

・安藤利奈,越智智佳子,伊藤裕子,山西祐輝,宮上紀之,永井将弘
治療開始時から有効性の評価を継続している脊髄性筋萎縮症5例の臨床経過

・竹永絢音,宮上紀之,ME.Choudhury,山本温人,中條滉太,向井直樹,塩川大介,永井将弘
加齢パーキンソン病モデルマウスにおけるミクログリア置換が及ぼす影響の検討